These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 28376831)

  • 1. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
    Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
    J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Let-7e Suppresses DNA Damage Repair and Sensitizes Ovarian Cancer to Cisplatin through Targeting PARP1.
    Xiao M; Guo J; Xie L; Yang C; Gong L; Wang Z; Cai J
    Mol Cancer Res; 2020 Mar; 18(3):436-447. PubMed ID: 31722968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
    BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
    Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
    Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
    Lee YK; Park NH; Lee H
    Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
    Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
    Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
    Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
    Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1.
    Wang Y; Bao W; Liu Y; Wang S; Xu S; Li X; Li Y; Wu S
    Cell Death Dis; 2018 May; 9(5):447. PubMed ID: 29670086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer.
    Biamonte F; Santamaria G; Sacco A; Perrone FM; Di Cello A; Battaglia AM; Salatino A; Di Vito A; Aversa I; Venturella R; Zullo F; Costanzo F
    Sci Rep; 2019 Apr; 9(1):5668. PubMed ID: 30952937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
    Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
    Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Discrimination and clinical value of plasma metabolomic profiles in multidrug resistant epithelial ovarian cancer].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):896-902. PubMed ID: 29262505
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer.
    Zhao H; Liu S; Wang G; Wu X; Ding Y; Guo G; Jiang J; Cui S
    Oncol Rep; 2015 Feb; 33(2):591-8. PubMed ID: 25482209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
    Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
    J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
    Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
    J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
    Shi L; Yu H; Zhang W; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
    Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
    Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.